Global Partners LP GLP
44.71 USD +0.44 (+0.99%)
Nov 12, 2026, 12:00 PM EST
44.18 Day range 44.84
39.58 52-week range 54.29
- YTD
- +6.83%
- 1 year
- +7.94%
News
zacks.com Best Value Stocks to Buy for November 12th PANL, GLP, and LRN made it to the Zacks Rank #1 (Strong Buy) value stocks list on November 12, 2026.
zacks.com Will Wegovy Pill Drive Renewed GLP-1 Growth Momentum for Novo Stock? NVO's Wegovy pill generated DKK 5.4 billion in Q3 sales, boosting obesity growth amid expanding global access and intensifying GLP-1 competition.
fxempire.com Sales of Pharmaceuticals, GLP-1s Send McKesson Shares to New Highs McKesson Corporation (MCK) shares up over 235% since May 2022 thanks to institutional support.
seekingalpha.com Hims & Hers Health: Don't Nitpick Quarterly Results Hims & Hers Health maintains robust growth prospects despite a minor Q3'26 revenue miss, leading to a market overreaction. HIMS strategically reduced marketing spend to prepare for the Eli Lilly…
fool.com Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy? Eli Lilly has been generating incredible growth in recent quarters due to its top GLP-1 drugs. Novo Nordisk has struggled due to sluggish numbers, but a higher-dose version of Wegovy could change…
globenewswire.com Conexeu Sciences Launches Human Collagen Initiative for Regenerative Aesthetics as GLP-1 Drives Demand for Tissue Restoration Highlights Conexeu has launched a human collagen initiative at its Vancouver research and development facility, for its aesthetics program, focused on potential tissue-restoration applications…
globenewswire.com Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek® 2026 SAN CARLOS, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company focused on diabetes and obesity, today announced that…
cnbc.com FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound The FDA is requiring the makers of all GLP-1 medications to add a warning about the potential increased risk of NAION. NAION is a rare condition caused by decreased blood flow to the front part of…
247wallst.com Eli Lilly May Have Just Found a New $23 Billion Market for Its GLP-1 Pill Eli Lilly (NYSE:LLY | LLY Price Prediction) just gave its newest drug a second act.
247wallst.com Global Partners Yields 7.15%. Is Its Dividend Safe? Twenty straight quarterly raises sound reassuring, but a wholesale margin windfall and softening retail demand are pulling in opposite directions at Global Partners. Which of those forces will decide…
zacks.com Here's Why Global Partners (GLP) Is a Great 'Buy the Bottom' Stock Now Global Partners (GLP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could…
globenewswire.com Zealand Pharma announces Boehringer Ingelheim's survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase 3 SYNCHRONIZE-CVOT trial with significant cardiometabolic benefits Company announcement – No. 55 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in…
prnewswire.com Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications – HARMONY IN DIVERSITY is the first study of combined neurotoxin and filler treatment in adults on glucagon-like peptide-1 (GLP-1) medications. In this Phase 4 cohort, participants reported…
marketbeat.com What Global Partners (GLP) Said on Its Q3 Earnings Call Global Partners NYSE: GLP reported higher third-quarter earnings as stronger wholesale margins more than offset lower retail fuel volumes, which executives attributed to higher pump prices.
seekingalpha.com Global Partners LP Common Units (GLP) Q3 2026 Earnings Call Transcript Global Partners LP Common Units (GLP) Q3 2026 Earnings Call Transcript
marketwatch.com Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying. As part of the agreement, Hims said it won't compound GLP-1 medications like Zepbound in the future.
zacks.com Should Value Investors Buy Global Partners (GLP) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the…
benzinga.com Global Partners Q3 2026 Earnings Call Transcript Global Partners (NYSE:GLP) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This content is powered by…
benzinga.com Global Partners Q3 EPS $1.26 Misses $1.61 Estimate, Sales $6.684B Miss $7.412B Estimate Global Partners (NYSE:GLP) reported quarterly earnings of $1.26 per share which missed the analyst consensus estimate of $1.61 by 21.74 percent. This is a 90.91 percent increase over earnings of…
businesswire.com Global Partners LP Reports Third-Quarter 2026 Financial Results NEWTON, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today reported financial results for the third quarter ended September 30, 2026. CEO Commentary…
defenseworld.net Reviewing Global Partners (NYSE:GLP) & Murphy Oil (NYSE:MUR) Murphy Oil (NYSE: MUR - Get Free Report) and Global Partners (NYSE: GLP - Get Free Report) are both energy companies, but which is the superior stock? We will compare the two companies based on the…
zacks.com Is Global Partners (GLP) a Solid Growth Stock? 3 Reasons to Think "Yes" Global Partners (GLP) could produce exceptional returns because of its solid growth attributes.
barrons.com Don't Lose Sleep Over GLP-1s: Why ResMed Is a Bargain ResMed, whose devices treat sleep apnea, has dropped on unfounded concerns that weight-loss drugs will replace its treatment. The stock is cheap and worth buying at current prices.
benzinga.com Global Partners Q2 EPS $1.86 Beats $1.24 Estimate, Sales $6.792B Miss $7.507B Estimate Global Partners (NYSE:GLP) reported quarterly earnings of $1.86 per share which beat the analyst consensus estimate of $1.24 by 50 percent. This is a 238.18 percent increase over earnings of $0.55…- benzinga.com Global Partners Q1 EPS $1.85 Beats $0.33 Estimate, Sales $5.322B Miss $6.976B Estimate Global Partners (NYSE:GLP) reported quarterly earnings of $1.85 per share which beat the analyst consensus estimate of $0.33 by 460.61 percent. This is a 413.89 percent increase over earnings of…
benzinga.com Stifel Maintains Hold on Global Partners, Raises Price Target to $46 Stifel analyst Selman Akyol maintains Global Partners (NYSE:GLP) with a Hold and raises the price target from $45 to $46.
benzinga.com Global Partners: Q4 Earnings Insights 
benzinga.com Earnings Scheduled For February 27, 2026 
benzinga.com Nasdaq Down Over 1% As Nvidia Shares Fall: Investor Sentiment Declines, Greed Index Moves To 'Fear' Zone Market sentiment declines, Nasdaq falls 1%. Nvidia down 5%, Salesforce up 4% in earnings. Initial jobless claims rise.
benzinga.com Dell, Block And 3 Stocks To Watch Heading Into Friday U.S. stock futures lower, Carter's and Dell report earnings, Global Partners and Block announce earnings, and Zscaler cuts sales guidance.
benzinga.com Preview: Global Partners's Earnings 
benzinga.com Stifel Maintains Hold on Global Partners, Lowers Price Target to $45 Stifel analyst Selman Akyol maintains Global Partners (NYSE:GLP) with a Hold and lowers the price target from $53 to $45.- benzinga.com Global Partners Q3 EPS $0.66 Misses $1.09 Estimate, Sales $4.694B Miss $7.211B Estimate Global Partners (NYSE:GLP) reported quarterly earnings of $0.66 per share which missed the analyst consensus estimate of $1.09 by 39.45 percent. This is a 43.59 percent decrease over earnings of…
benzinga.com Earnings Scheduled For November 7, 2025 
benzinga.com A Look Ahead: Global Partners's Earnings Forecast 
benzinga.com Top 3 Energy Stocks That May Rocket Higher In October - benzinga.com Earnings Scheduled For August 7, 2025
benzinga.com Wall Street Rallies After US Seals First Trade Deal: 'You Better Go Out And Buy Stock,' Trump Says U.S. stocks rallied Thursday after the Trump administration signed its first major trade agreement with the United Kingdom, igniting optimism about further global deals — especially with China — and…
benzinga.com Earnings Scheduled For May 8, 2025 - benzinga.com Earnings Scheduled For February 28, 2025
- benzinga.com Earnings Scheduled For February 28, 2024 Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion.
benzinga.com Earnings Scheduled For November 9, 2023 Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.- benzinga.com Earnings Scheduled For August 4, 2023 Companies Reporting Before The Bell • WPP (NYSE:WPP) is projected to report earnings for its first quarter. • Anglogold Ashanti (NYSE:AU) is likely to report earnings for its first quarter.
- benzinga.com Earnings Scheduled For May 5, 2023 Companies Reporting Before The Bell • CNH Industrial (NYSE:CNHI) is estimated to report quarterly earnings at $0.32 per share on revenue of $5.08 billion.
- benzinga.com 5 Value Stocks To Watch In The Energy Sector
- benzinga.com Earnings Scheduled For February 27, 2023 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.
- benzinga.com Earnings Scheduled For November 4, 2022 Companies Reporting Before The Bell • Sprott (NYSE:SII) is likely to report quarterly earnings at $0.49 per share on revenue of $49.95 million. • Telefonica (NYSE:TEF) is likely to report earnings…
benzinga.com Why Sonnet BioTherapeutics Shares Surged Over 66%; Here Are 63 Biggest Movers From Yesterday Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) climbed 66.4% to close at $1.93 on Monday after the company announced an agreement with Janssen for the evaluation of three Sonnet product…- benzinga.com Earnings Scheduled For August 5, 2022 Companies Reporting Before The Bell • Reservoir Media (NASDAQ:RSVR) is projected to report quarterly loss at $0.05 per share on revenue of $18.19 million.
- benzinga.com Earnings Scheduled For May 6, 2022 Companies Reporting Before The Bell • Brookfield Renewable (NYSE:BEP) is expected to report quarterly loss at $0.02 per share on revenue of $1.27 billion.